1. de Rooij NK, Linn FH, van der Plas JA, Algra A, Rinkel GJ. Incidence of subarachnoid haemorrhage: a systematic review with emphasis on region, age, gender and time trends. J Neurol Neurosurg Psychiatry. 2007;78 12:1365-72; doi: 10.1136/jnnp.2007.117655.
2. Rinkel GJ, Algra A. Long-term outcomes of patients with aneurysmal subarachnoid haemorrhage. Lancet Neurol. 2011;10 4:349-56; doi: 10.1016/s1474-4422(11)70017-5.
3. Tanno Y, Homma M, Oinuma M, Kodama N, Ymamoto T. Rebleeding from ruptured intracranial aneurysms in North Eastern Province of Japan. A cooperative study. J Neurol Sci. 2007;258 1-2:11-6; doi: 10.1016/j.jns.2007.01.074.
4. Larsen CC, Astrup J. Rebleeding after aneurysmal subarachnoid hemorrhage: a literature review. World Neurosurg. 2013;79 2:307-12; doi: 10.1016/j.wneu.2012.06.023.
5. Roos YB, Rinkel GJ, Vermeulen M, Algra A, van Gijn J. Antifibrinolytic therapy for aneurysmal subarachnoid haemorrhage. Cochrane Database Syst Rev. 2003; 2:Cd001245; doi: 10.1002/14651858.Cd001245.
6. Baharoglu MI, Germans MR, Rinkel GJ, Algra A, Vermeulen M, van Gijn J, et al. Antifibrinolytic therapy for aneurysmal subarachnoid haemorrhage. Cochrane Database Syst Rev. 2013; 8:Cd001245; doi: 10.1002/14651858.CD001245.pub2.
7. Post R, Germans MR, Tjerkstra MA, Vergouwen MDI, Jellema K, Koot RW, et al. Ultra-early tranexamic acid after subarachnoid haemorrhage (ULTRA): a randomised controlled trial. Lancet. 2021;397 10269:112-8; doi: 10.1016/s0140-6736(20)32518-6.
8. Lo BWY, Fukuda H, Tsang ACO, Langer DJ, Miyawaki S, Koyanagi M, et al. Commentary on Post, et al. Ultra-early tranexamic acid after subarachnoid hemorrhage: A randomized controlled trial. Lancet 2021. Surg Neurol Int. 2021;12:156; doi: 10.25259/sni_242_2021.
9. Eastin TR, Snipes CD, Seupaul RA. Are antifibrinolytic agents effective in the treatment of aneurysmal subarachnoid hemorrhage? Ann Emerg Med. 2014;64 6:658-9; doi: 10.1016/j.annemergmed.2014.06.004.
10. Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. Bmj. 2011;343:d5928; doi: 10.1136/bmj.d5928.
11. Hillman J, Fridriksson S, Nilsson O, Yu Z, Saveland H, Jakobsson KE. Immediate administration of tranexamic acid and reduced incidence of early rebleeding after aneurysmal subarachnoid hemorrhage: a prospective randomized study. J Neurosurg. 2002;97 4:771-8; doi: 10.3171/jns.2002.97.4.0771.
12. Roos Y. Antifibrinolytic treatment in subarachnoid hemorrhage: a randomized placebo-controlled trial. STAR Study Group. Neurology. 2000;54 1:77-82; doi: 10.1212/wnl.54.1.77.
13. Tsementzis SA, Hitchcock ER, Meyer CH. Benefits and risks of antifibrinolytic therapy in the management of ruptured intracranial aneurysms. A double-blind placebo-controlled study. Acta Neurochir (Wien). 1990;102 1-2:1-10; doi: 10.1007/bf01402177.
14. Wijdicks EF, Hasan D, Lindsay KW, Brouwers PJ, Hatfield R, Murray GD, et al. Short-term tranexamic acid treatment in aneurysmal subarachnoid hemorrhage. Stroke. 1989;20 12:1674-9; doi: 10.1161/01.str.20.12.1674.
15. Vermeulen M, Lindsay KW, Murray GD, Cheah F, Hijdra A, Muizelaar JP, et al. Antifibrinolytic treatment in subarachnoid hemorrhage. N Engl J Med. 1984;311 7:432-7; doi: 10.1056/nejm198408163110703.
16. Fodstad H, Forssell A, Liliequist B, Schannong M. Antifibrinolysis with tranexamic acid in aneurysmal subarachnoid hemorrhage: a consecutive controlled clinical trial. Neurosurgery. 1981;8 2:158-65; doi: 10.1227/00006123-198102000-00004.
17. Germans MR, Coert BA, Vandertop WP, Verbaan D. Time intervals from subarachnoid hemorrhage to rebleed. J Neurol. 2014;261 7:1425-31; doi: 10.1007/s00415-014-7365-0.
18. Post R, Germans MR, Boogaarts HD, Ferreira Dias Xavier B, Van den Berg R, Coert BA, et al. Short-term tranexamic acid treatment reduces in-hospital mortality in aneurysmal sub-arachnoid hemorrhage: A multicenter comparison study. PLoS One. 2019;14 2:e0211868; doi: 10.1371/journal.pone.0211868.
19. Carley S, Sen A. Best evidence topic report. Antifibrinolytics for the initial management of sub arachnoid haemorrhage. Emerg Med J. 2005;22 4:274-5; doi: 10.1136/emj.2005.023523.
20. Chwajol M, Starke RM, Kim GH, Mayer SA, Connolly ES. Antifibrinolytic therapy to prevent early rebleeding after subarachnoid hemorrhage. Neurocrit Care. 2008;8 3:418-26; doi: 10.1007/s12028-008-9088-5.
21. Vel R, Udupi BP, Satya Prakash MV, Adinarayanan S, Mishra S, Babu L. Effect of low dose tranexamic acid on intra-operative blood loss in neurosurgical patients. Saudi J Anaesth. 2015;9 1:42-8; doi: 10.4103/1658-354x.146304.
22. Mahdy AM, Webster NR. Perioperative systemic haemostatic agents. Br J Anaesth. 2004;93 6:842-58; doi: 10.1093/bja/aeh227.
23. Connolly ES, Jr., Rabinstein AA, Carhuapoma JR, Derdeyn CP, Dion J, Higashida RT, et al. Guidelines for the management of aneurysmal subarachnoid hemorrhage: a guideline for healthcare professionals from the American Heart Association/american Stroke Association. Stroke. 2012;43 6:1711-37; doi: 10.1161/STR.0b013e3182587839.
24. Jimenez JJ, Iribarren JL, Lorente L, Rodriguez JM, Hernandez D, Nassar I, et al. Tranexamic acid attenuates inflammatory response in cardiopulmonary bypass surgery through blockade of fibrinolysis: a case control study followed by a randomized double-blind controlled trial. Crit Care. 2007;11 6:R117; doi: 10.1186/cc6173.
25. Teng Y, Feng C, Liu Y, Jin H, Gao Y, Li T. Anti-inflammatory effect of tranexamic acid against trauma-hemorrhagic shock-induced acute lung injury in rats. Exp Anim. 2018;67 3:313-20; doi: 10.1538/expanim.17-0143.
26. Fodstad H, Nilsson IM. Coagulation and fibrinolysis in blood and cerebrospinal fluid after aneurysmal subarachnoid haemorrhage: effect of tranexamic acid (AMCA). Acta Neurochir (Wien). 1981;56 1-2:25-38; doi: 10.1007/bf01400969.
27. Adams HP, Jr., Kassell NF, Torner JC, Haley EC, Jr. Predicting cerebral ischemia after aneurysmal subarachnoid hemorrhage: influences of clinical condition, CT results, and antifibrinolytic therapy. A report of the Cooperative Aneurysm Study. Neurology. 1987;37 10:1586-91; doi: 10.1212/wnl.37.10.1586.
28. Hijdra A, van Gijn J, Nagelkerke NJ, Vermeulen M, van Crevel H. Prediction of delayed cerebral ischemia, rebleeding, and outcome after aneurysmal subarachnoid hemorrhage. Stroke. 1988;19 10:1250-6; doi: 10.1161/01.str.19.10.1250.
29. Pinna G, Pasqualin A, Vivenza C, Da Pian R. Rebleeding, ischaemia and hydrocephalus following anti-fibrinolytic treatment for ruptured cerebral aneurysms: a retrospective clinical study. Acta Neurochir (Wien). 1988;93 3-4:77-87; doi: 10.1007/bf01402885.
30. Vergouwen MD, Vermeulen M, van Gijn J, Rinkel GJ, Wijdicks EF, Muizelaar JP, et al. Definition of delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage as an outcome event in clinical trials and observational studies: proposal of a multidisciplinary research group. Stroke. 2010;41 10:2391-5; doi: 10.1161/strokeaha.110.589275.
31. Steiner T, Juvela S, Unterberg A, Jung C, Forsting M, Rinkel G. European Stroke Organization guidelines for the management of intracranial aneurysms and subarachnoid haemorrhage. Cerebrovasc Dis. 2013;35 2:93-112; doi: 10.1159/000346087.
32. Anker-Moller T, Troldborg A, Sunde N, Hvas AM. Evidence for the Use of Tranexamic Acid in Subarachnoid and Subdural Hemorrhage: A Systematic Review. Seminars in Thrombosis and Hemostasis. 2017;43 7:750-8; doi: 10.1055/s-0037-1604089.
33. Mehta V, Holness RO, Connolly K, Walling S, Hall R. Acute hydrocephalus following aneurysmal subarachnoid hemorrhage. Can J Neurol Sci. 1996;23 1:40-5; doi: 10.1017/s0317167100039160.
34. Hasan D, Vermeulen M, Wijdicks EF, Hijdra A, van Gijn J. Management problems in acute hydrocephalus after subarachnoid hemorrhage. Stroke. 1989;20 6:747-53; doi: 10.1161/01.str.20.6.747.
35. McIver JI, Friedman JA, Wijdicks EF, Piepgras DG, Pichelmann MA, Toussaint LG, 3rd, et al. Preoperative ventriculostomy and rebleeding after aneurysmal subarachnoid hemorrhage. J Neurosurg. 2002;97 5:1042-4; doi: 10.3171/jns.2002.97.5.1042.
36. Chen S, Luo J, Reis C, Manaenko A, Zhang J. Hydrocephalus after Subarachnoid Hemorrhage: Pathophysiology, Diagnosis, and Treatment. Biomed Res Int. 2017;2017:8584753; doi: 10.1155/2017/8584753.
37. Fountas KN, Kapsalaki EZ, Machinis T, Karampelas I, Smisson HF, Robinson JS. Review of the literature regarding the relationship of rebleeding and external ventricular drainage in patients with subarachnoid hemorrhage of aneurysmal origin. Neurosurg Rev. 2006;29 1:14-8; discussion 9-20; doi: 10.1007/s10143-005-0423-4.
38. Paré L, Delfino R, Leblanc R. The relationship of ventricular drainage to aneurysmal rebleeding. J Neurosurg. 1992;76 3:422-7; doi: 10.3171/jns.1992.76.3.0422.
39. Yutthakasemsunt S, Kittiwatanagul W, Piyavechvirat P, Thinkamrop B, Phuenpathom N, Lumbiganon P. Tranexamic acid for patients with traumatic brain injury: a randomized, double-blinded, placebo-controlled trial. BMC Emerg Med. 2013;13:20; doi: 10.1186/1471-227x-13-20.
40. Fakharian E, Abedzadeh-Kalahroudi M, Atoof F. Effect of Tranexamic Acid on Prevention of Hemorrhagic Mass Growth in Patients with Traumatic Brain Injury. World Neurosurg. 2018;109:e748-e53; doi: 10.1016/j.wneu.2017.10.075.
41. Brenner A, Belli A, Chaudhri R, Coats T, Frimley L, Jamaluddin SF, et al. Understanding the neuroprotective effect of tranexamic acid: an exploratory analysis of the CRASH-3 randomised trial. Crit Care. 2020;24 1:560; doi: 10.1186/s13054-020-03243-4.
42. Williams-Johnson JA, McDonald AH, Strachan GG, Williams EW. Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2) A randomised, placebo-controlled trial. West Indian Med J. 2010;59 6:612-24.
43. Chakroun-Walha O, Samet A, Jerbi M, Nasri A, Talbi A, Kanoun H, et al. Benefits of the tranexamic acid in head trauma with no extracranial bleeding: a prospective follow-up of 180 patients. Eur J Trauma Emerg Surg. 2019;45 4:719-26; doi: 10.1007/s00068-018-0974-z.
44. Walker PF, Bozzay JD, Johnston LR, Elster EA, Rodriguez CJ, Bradley MJ. Outcomes of tranexamic acid administration in military trauma patients with intracranial hemorrhage: a cohort study. BMC Emerg Med. 2020;20 1:39; doi: 10.1186/s12873-020-00335-w.
45. July J, Pranata R. Tranexamic acid is associated with reduced mortality, hemorrhagic expansion, and vascular occlusive events in traumatic brain injury - meta-analysis of randomized controlled trials. BMC Neurol. 2020;20 1:119; doi: 10.1186/s12883-020-01694-4.
46. Lawati KA, Sharif S, Maqbali SA, Rimawi HA, Petrosoniak A, Belley-Cote EP, et al. Efficacy and safety of tranexamic acid in acute traumatic brain injury: a systematic review and meta-analysis of randomized-controlled trials. Intensive Care Med. 2021;47 1:14-27; doi: 10.1007/s00134-020-06279-w.
47. Hasan D, Schonck RS, Avezaat CJ, Tanghe HL, van Gijn J, van der Lugt PJ. Epileptic seizures after subarachnoid hemorrhage. Ann Neurol. 1993;33 3:286-91; doi: 10.1002/ana.410330310.
48. Lanzino G, D'Urso PI, Suarez J. Seizures and anticonvulsants after aneurysmal subarachnoid hemorrhage. Neurocrit Care. 2011;15 2:247-56; doi: 10.1007/s12028-011-9584-x.
49. Schlag MG, Hopf R, Zifko U, Redl H. Epileptic seizures following cortical application of fibrin sealants containing tranexamic acid in rats. Acta Neurochir (Wien). 2002;144 1:63-9; doi: 10.1007/s701-002-8275-z.
50. Lecker I, Wang DS, Whissell PD, Avramescu S, Mazer CD, Orser BA. Tranexamic acid-associated seizures: Causes and treatment. Ann Neurol. 2016;79 1:18-26; doi: 10.1002/ana.24558.
51. Furtmüller R, Schlag MG, Berger M, Hopf R, Huck S, Sieghart W, et al. Tranexamic acid, a widely used antifibrinolytic agent, causes convulsions by a gamma-aminobutyric acid(A) receptor antagonistic effect. J Pharmacol Exp Ther. 2002;301 1:168-73; doi: 10.1124/jpet.301.1.168.
52. Takagi H, Ando T, Umemoto T. Seizures associated with tranexamic acid for cardiac surgery: a meta-analysis of randomized and non-randomized studies. J Cardiovasc Surg (Torino). 2017;58 4:633-41; doi: 10.23736/s0021-9509.17.09877-9.
53. Rowell SE, Meier EN, McKnight B, Kannas D, May S, Sheehan K, et al. Effect of Out-of-Hospital Tranexamic Acid vs Placebo on 6-Month Functional Neurologic Outcomes in Patients With Moderate or Severe Traumatic Brain Injury. Jama. 2020;324 10:961-74; doi: 10.1001/jama.2020.8958.